The general mood among these heavyweight investors is divided, with 63% leaning bullish and 36% bearish. Among these notable ...

Recently reported positive preliminary data from Phase 1 dose escalation trial of micvotabart pelidotin ("MICVO," formerly PYX-201), including a confirmed 50% objective response rate by RECIST 1.1 ...

Merck & Co. Inc. closed 29.59% below its 52-week high of $134.63, which the company reached on June 25th.

Merck KGaA's stock remains a 'hold' due to its high valuation, trading at an earnings multiple of around 20 and a 4.5% free ...

Digital physical therapy startup Hinge Health filed its IPO prospectus with the SEC on Monday. The company's revenue jumped 33% in 2024 to $390 million. Hinge Health uses software to help patients ...

Out of all of the special options we uncovered, 3 are puts, for a total amount of $141,686, and 10 are calls, for a total ...

Preparations for submission of a Biologics License Application (BLA) for Cylembio® (imsapepimut and etimupepimut, adjuvanted) to FDA by year end 2025 remain on track. The trial completed enrollment in ...

Investors in Merck & Co Inc (Symbol: MRK) saw new options begin trading today, for the April 11th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the MRK ...

Merck, also known as MSD outside the U.S. and Canada, plans to significantly expand its workforce in India, aiming for around 2,700 employees by the year's end. The company focuses on therapy areas ...

Mer­ck said its “once-in-a-life­time” drug Keytru­da could be sub­ject to price re­duc­tions un­der the In­fla­tion Re­duc­tion Act, which would lead to a … ...

Merck is bracing for the years of sales growth from oncology superstar Keytruda to take a sharp turn in 2028—and for more reasons than one. Along with a key U.S. patent expiring at the end of ...